NO20075662L - Roflumilast for behandlingen av pulmonal hypertensjon - Google Patents

Roflumilast for behandlingen av pulmonal hypertensjon

Info

Publication number
NO20075662L
NO20075662L NO20075662A NO20075662A NO20075662L NO 20075662 L NO20075662 L NO 20075662L NO 20075662 A NO20075662 A NO 20075662A NO 20075662 A NO20075662 A NO 20075662A NO 20075662 L NO20075662 L NO 20075662L
Authority
NO
Norway
Prior art keywords
roflumilast
treatment
pulmonary hypertension
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20075662A
Other languages
English (en)
Norwegian (no)
Inventor
Armin Hatzelmann
Christian Schudt
Rolf Beume
Degenhard Marx
Hermann Tenor
Saadia Eddahibi
Serge Adnot
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of NO20075662L publication Critical patent/NO20075662L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20075662A 2005-04-19 2007-11-07 Roflumilast for behandlingen av pulmonal hypertensjon NO20075662L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103147 2005-04-19
PCT/EP2006/061557 WO2006111495A1 (en) 2005-04-19 2006-04-12 Roflumilast for the treatment of pulmonary hypertension

Publications (1)

Publication Number Publication Date
NO20075662L true NO20075662L (no) 2007-11-07

Family

ID=34939388

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075662A NO20075662L (no) 2005-04-19 2007-11-07 Roflumilast for behandlingen av pulmonal hypertensjon

Country Status (24)

Country Link
US (1) US8648100B2 (ko)
EP (2) EP2366393B1 (ko)
JP (2) JP2008536888A (ko)
KR (1) KR101358479B1 (ko)
CN (2) CN101163476A (ko)
AU (1) AU2006237300B2 (ko)
BR (1) BRPI0610498A2 (ko)
CA (1) CA2604295C (ko)
CY (1) CY1114468T1 (ko)
DK (1) DK2366393T3 (ko)
EA (1) EA016037B1 (ko)
ES (1) ES2433661T3 (ko)
HR (1) HRP20130982T1 (ko)
IL (2) IL186538A0 (ko)
ME (1) ME01609B (ko)
MX (1) MX2007012711A (ko)
NO (1) NO20075662L (ko)
NZ (1) NZ561746A (ko)
PL (1) PL2366393T3 (ko)
PT (1) PT2366393E (ko)
RS (1) RS52944B (ko)
SI (1) SI2366393T1 (ko)
WO (1) WO2006111495A1 (ko)
ZA (1) ZA200707930B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
WO2009115235A1 (en) * 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of pulmonary hypertension
NZ710726A (en) * 2013-01-28 2020-08-28 Incozen Therapeutics Pvt Ltd Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN107038965A (zh) * 2017-05-05 2017-08-11 深圳浩翔光电技术有限公司 Led显示装置、成型模组、及其生产工艺
KR20190005708A (ko) 2017-07-05 2019-01-16 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물
CN115969847A (zh) * 2023-02-03 2023-04-18 华中科技大学 罗氟司特在制备治疗心力衰竭的药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB371800A (en) 1929-10-21 1932-04-28 Willem Zaadnoordijk A process of filtering gases and fogs
GB343664A (en) 1929-12-27 1931-02-26 William Duncan Grant Subaquatic rock drilling devices
GB357903A (en) 1931-01-05 1931-10-01 Oskar Rosenfelder Improvements in catamenial appliances and infants' diapers
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
EP0706513B1 (de) 1993-07-02 2002-05-15 Byk Gulden Lomberg Chemische Fabrik GmbH Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
AU6823098A (en) * 1997-02-28 1998-09-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
NZ338075A (en) 1997-04-25 2000-10-27 Pfizer Ltd Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction
FR2762841B1 (fr) 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
EP2295436A1 (de) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
CA2329077C (en) 1998-04-20 2007-09-18 Pfizer Inc. Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
DE19819023A1 (de) 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
WO2000056719A1 (en) 1999-03-22 2000-09-28 Bristol-Myers Squibb Company FUSED PYRIDOPYRIDAZINE INHIBITORS OF cGMP PHOSPHODIESTERASE
PT1219609E (pt) 1999-09-16 2007-06-19 Tanabe Seiyaku Co ''compostos cíclicos aromático azotados de seis membros''
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
PL364910A1 (en) 2001-01-31 2004-12-27 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
EE200300362A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid
US20020174207A1 (en) * 2001-02-28 2002-11-21 Abdella Battou Self-healing hierarchical network management system, and methods and apparatus therefor
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
EP1441730B1 (en) * 2001-11-05 2006-08-09 Merck Patent GmbH Hydrazono-malonitriles
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
JP2005532321A (ja) * 2002-05-16 2005-10-27 ファルマシア コーポレーション 呼吸器の疾患および状態の、選択的ｉＮＯＳ阻害剤とＰＤＥ阻害剤による治療方法、ならびにそのための組成物
WO2004072079A1 (en) 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EP1634606A1 (en) * 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Drug for airway administration
NZ544040A (en) 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
WO2004105751A1 (en) * 2003-05-28 2004-12-09 Glaxo Group Limited Traitement of cardiovascular pathology
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
US7132435B2 (en) 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
RU2006108864A (ru) 2003-08-22 2007-09-27 Берингер Ингельхайм Фармасьютиклз, Инк. (Us) Способы лечения хронического обструктивного заболевания легких (хозл) и легочной гипертензии
MXPA06012279A (es) 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.

Also Published As

Publication number Publication date
MX2007012711A (es) 2008-01-11
EP2366393A2 (en) 2011-09-21
ME01609B (me) 2014-09-20
IL186538A0 (en) 2008-06-05
PT2366393E (pt) 2013-10-04
BRPI0610498A2 (pt) 2010-06-22
CN101163476A (zh) 2008-04-16
SI2366393T1 (sl) 2013-12-31
ES2433661T3 (es) 2013-12-12
NZ561746A (en) 2011-09-30
US20090215836A1 (en) 2009-08-27
EA016037B1 (ru) 2012-01-30
CA2604295A1 (en) 2006-10-26
AU2006237300B2 (en) 2011-10-13
WO2006111495A1 (en) 2006-10-26
KR101358479B1 (ko) 2014-02-06
JP2013237683A (ja) 2013-11-28
CA2604295C (en) 2014-10-07
EP2366393B1 (en) 2013-08-07
CN102614176A (zh) 2012-08-01
ZA200707930B (en) 2008-05-28
AU2006237300A1 (en) 2006-10-26
CY1114468T1 (el) 2017-01-25
JP2008536888A (ja) 2008-09-11
HRP20130982T1 (hr) 2013-11-22
KR20080002950A (ko) 2008-01-04
IL218745A0 (en) 2012-05-31
EA200702201A1 (ru) 2008-04-28
RS52944B (en) 2014-02-28
US8648100B2 (en) 2014-02-11
EP2366393A3 (en) 2011-09-28
EP1874309A1 (en) 2008-01-09
PL2366393T3 (pl) 2014-01-31
DK2366393T3 (da) 2013-10-21

Similar Documents

Publication Publication Date Title
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
NO20071095L (no) Hittil ukjente tiofenderivater
ME00936B (me) Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
EA200870409A1 (ru) Антагонисты киназы pi3
EA201070786A1 (ru) Бензофуропиримидиноны
DE602008002934D1 (de) 2-cyclopropylthiazolderivate
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon
RS50807B (sr) 3,11 b-cis-dihidrotetrabenazin za lečenje šizofrenije i drugih psihoza
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
UY29246A1 (es) Nuevos compuestos
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
NO20082793L (no) Nye tiofenderivater
DE602006007037D1 (de) Pyrrolotriazin-kinasehemmer
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
NO20092146L (no) Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en 5-HT1A-agonist, i behandlingen av seksuell dysfunksjon
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
TW200744593A (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
EA200801199A1 (ru) Ингибиторы киназы
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

FC2A Withdrawal, rejection or dismissal of laid open patent application